29 Sep 2017 11:20
29 September 2017
Rule 2.9 Announcement
In accordance with Rule 2.9 of the City Code on Takeovers and Mergers, Clinigen Group plc (the "Company") confirms that, as at the date of this announcement, its issued share capital consists of 115,365,225 ordinary shares of 0.1 pence each with International Securities Identification Number GB00B89J2419. The Company holds no shares in treasury.
-Ends-
Contact details
Clinigen Group plc | Tel: +44 (0) 1283 495010 |
Shaun Chilton, Group Chief Executive Officer | |
Martin Abell, Group Chief Financial Officer | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) James Black / Tom Ballard (Corporate Broking) | |
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas / Jack Wood | |
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Adrian Duffield / Melanie Toyne-Sewell / Alex Shaw | Email: clinigen@instinctif.com |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
For more information, please visit www.clinigengroup.com